Focus: Insulet is a public medical device company headquartered in Massachusetts that designs and manufactures the Omnipod insulin pump system for diabetes management. The company generates $1.7B in annual revenue with a focused market position in automated glucose control.
Profile data last refreshed 11h ago · AI intelligence enriched 1mo ago
Hot — 227 jobs added in 30d
Net +32 (227 new, 195 removed). Aggressive expansion phase.
Best fit for commercial and manufacturing professionals seeking growth-stage device company exposure; R&D candidates should assess comfort with incremental innovation cycle.
Help build intelligence for Insulet
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Insulet's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Insulet, Calm join forces for diabetes care offerings with ‘Mind in Range’ wellness tools - Fierce Pharma
Insulet, Calm join forces for diabetes care offerings with ‘Mind in Range’ wellness tools Fierce Pharma
Insulet has a new chief R&D officer - Drug Delivery Business
Insulet has a new chief R&D officer Drug Delivery Business
The biggest diabetes tech news out of ADA 2026 - Drug Delivery Business
The biggest diabetes tech news out of ADA 2026 Drug Delivery Business
Insulet data backs Omnipod 6, fully closed-loop AID systems - Drug Delivery Business
Insulet data backs Omnipod 6, fully closed-loop AID systems Drug Delivery Business
Insulet initiates another Omnipod 5 recall affecting 7 million devices including some Dash, Eros systems - Drug Delivery Business
Insulet initiates another Omnipod 5 recall affecting 7 million devices including some Dash, Eros systems Drug Delivery Business
Insulet CEO details ‘Scrubs’ device promotion win as it boosts awareness, education drive - Fierce Pharma
Insulet CEO details ‘Scrubs’ device promotion win as it boosts awareness, education drive Fierce Pharma
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Simplifying meal bolusing with Omnipod 5: real-world outcomes to support simplified user-initiated insulin dosing strategies in managing type 1 or type 2 diabetes.
Diabetes-related acute care utilization following initiation of automated insulin delivery (AID): A comparison of a disposable tubeless AID system and durable tubed systems.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo